Study of new heart device leads and tricuspid valve leakage
Part of Heart & circulation clinical trials.
This study looks at how a new pacemaker or defibrillator lead may affect the tricuspid valve (the valve between the right upper and lower heart chambers). It helps doctors understand if the lead causes leakage (regurgitation) over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You need a pacemaker, ICD, or CRT device for the first time (no leads already in place).
- You should not have severe tricuspid regurgitation (leaky valve) before the procedure.
- No other severe heart valve problems that need treatment.
- No high blood pressure in the lungs (pulmonary hypertension) that is significant.
- No structural heart disease affecting the right ventricle (like certain cardiomyopathies).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how heart devices like pacemakers affect the tricuspid valve over time. It uses ultrasound to check valve function and see if the device causes any problems.
This study tests a new device to help people with severe tricuspid regurgitation (leaky heart valve) who are at higher risk from surgery. It aims to see if the device can reduce the leak and improve symptoms.
This study tests a new way to place a defibrillator lead in a vein on the heart's surface, avoiding the tricuspid valve. It may help people who need a defibrillator but have a leaky tricuspid valve that could worsen with standard lead placement.
This study tests a new device to fix a leaky tricuspid valve without open-heart surgery. It is for people with severe leakage who are considered too high-risk for traditional surgery.
This trial tests a new catheter-based device to replace your tricuspid valve without open-heart surgery. It's for people with severe tricuspid regurgitation who are at high risk for surgery.
This study looks at how a new pacemaker or defibrillator (CIED) might affect the tricuspid valve and the right side of the heart. It aims to understand these changes over time.
Hear when a new Tricuspid Valve Regurgitation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.